Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: Effects of αvβ 3 and αIIbβ3 antagonists

Clinical and Experimental Metastasis

Volumn 21, Issue 6, 2004, Pages 553-561

  Gomes, Noëlia ^a   Vassy, Jany ^a   Lebos, Claude ^b   Arbeille, Brigitte ^b   Legrand, Chantal ^a   Fauvel Lafeve, Françoise ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b CHU BRETONNEAU   (France)

Author keywords

Adhesion; Extracellular matrix; Integrin; Integrin antagonists; Platelet; Shear rate; Tumour cell

Indexed keywords

ANTINEOPLASTIC AGENT; LAMIFIBAN; SB 273005; UNCLASSIFIED DRUG;

ARTICLE; BLOOD FLOW; BREAST ADENOCARCINOMA; CELL ADHESION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; FLOW RATE; HUMAN; HUMAN CELL; INCUBATION TIME; SHEAR RATE; THROMBOCYTE; TUMOR CELL CULTURE; VASCULAR ENDOTHELIUM;

ACETATES; ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; BLOOD VESSELS; BREAST NEOPLASMS; CELL ADHESION; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTEGRIN ALPHAVBETA3; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES; RECEPTORS, VITRONECTIN; REGIONAL BLOOD FLOW; TUMOR CELLS, CULTURED; TYROSINE;

EID: 12544252093     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-004-3756-4     Document Type: Article

References (50)

1. Weiss L. Metastatic inefficiency. Adv Cancer Res 1990; 54: 159-211.
2. Zetter BR. The cellular basis of site-specific tumor metastasis. N Engl J Med 1990; 322(9): 605-12.
3. Xiong JP, Stehle T, Goodman SL et al. Integrins, cations and ligands: making the connection. J Thromb Haemost 2003; 1(7): 1642-54.
4. Ginsberg MH, Du X, Plow EF. Inside-out integrin signalling. Curr Opin Cell Biol 1992; 4(5): 766-71.
5. Albelda SM, Mette SA, Elder DE et al. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 1990; 50(20): 6757-64.
6. Pignatelli M, Cardillo MR, Hanby A et al. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol 1992; 23(10): 1159-66.
7. Ria R, Vacca A, Ribatti D et al. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002; 87(8): 836-45.
8. Horton MA. The alpha v beta 3 integrin 'vitronectin receptor'. Int J Biochem Cell Biol 1997; 29(5): 721-5.
9. Lawler J, Hynes RO. An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin. Blood 1989; 74(6): 2022-7.
10. Denis C, Williams JA, Lu X et al. Solid-phase von Willebrand factor contains a conformationally active RGD motif that mediates endothelial cell adhesion through the alpha v beta 3 receptor. Blood 1993; 82(12): 3622-30.
11. Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med 1981; 95(5): 636-41.
12. Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 1992; 11(3-4): 325-51.
13. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61(1): 46-52.
14. Nieswandt B, Hafner M, Echtenacher B et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59(6): 1295-300.
15. Bastida E, Almirall L, Ordinas A. Platelet and shear rate promote tumor cell adhesion to human endothelial extracellular matrix -absence of a role for platelet cyclooxygenase. Thromb Haemost 1989; 61(3): 485-9.
16. Dardik R, Kaufmann Y, Savion N et al. Platelets mediate tumor cell adhesion to the subendothelium under flow conditions: involvement of platelet GPIIb-IIIa and tumor cell alpha(v) integrins. Int J Cancer 1997; 70(2): 201-7.
17. Parise LV. Integrin alpha(IIb)beta(3) signaling in platelet adhesion and aggregation. Curr Opin Cell Biol 1999; 11(5): 597-601.
18. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995; 74(1): 282-90.
19. Felding-Habermann B, Habermann R, Saldivar E et al. Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J Biol Chem 1996; 271(10): 5892-900.
20. Felding-Habermann B, O'Toole TE, Smith JW et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001; 98(4): 1853-8.
21. Alig L, Edenhofer A, Hadvary P et al. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992; 35(23): 4393-407.
22. Miller WH, Alberts DP, Bhatnagar PK et al. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J Med Chem 2000; 43(1): 22-6.
23. Tam SH, Sassoli PM, Jordan RE et al. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998; 98(11): 1085-91.
24. Coller BS. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J Clin Invest 1997; 99(7): 1467-71.
25. Incardona F, Calvo F, Fauvel-Lafeve F et al. Involvement of thrombospondin in the adherence of human breast-adenocarcinoma cells: A possible role in the metastatic process. Int J Cancer 1993; 55(3): 471-7.
26. Jaffe EA, Nachman RL, Becker CG et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52(11): 2745-56.
27. Bonnefoy A, Harsfalvi J, Pfliegler G et al. The subendothelium of the HMEC-1 cell line supports thrombus formation in the absence of von Willebrand factor and collagen types I, III and VI. Thromb Haemost 2001; 85(3): 552-9.
28. Murphy NP, Pratico D, Fitzgerald DJ. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo. J Pharmacol Exp Ther 1998; 286(2): 945-51.
29. Kuwahara M, Sugimoto M, Tsuji S et al. Comparative studies on the antiplatelet effects of a humanized anti-platelet glycoprotein IIb/IIIa antibody (YM337) and ReoPro under flow conditions. Thromb Haemost 1998; 80(1): 28-31.
30. Sakariassen KS, Aarts PA, de Groot PG et al. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983; 102(4): 522-35.
31. Lafeve F, Meric A, Arbeille B et al. Spectrophotometric evaluation of the adhesion of blood platelets to collagen and microfibrils. Thromb Res 1993; 71(3): 193-204.
32. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004; 83(3): 249-89.
33. Konstantopoulos K, Kamat SG, Schafer AI et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation 1995; 91(5): 1427-31.
34. Goldsmith HL, Turitto VT. Rheological aspects of thrombosis and haemostasis: Basic principles and applications. ICTH-Report - Subcommittee on Rheology of the International Committee on Thrombosis and Haemostasis. Thromb Haemost 1986; 55(3): 415-35.
35. Miller WH, Keenan RM, Willette RN et al. Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor). Drug Discov Today 2000; 5(9): 397-48.
36. Al-Mehdi AB, Tozawa K, Fisher AB et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: A new model for metastasis. Nat Med 2000; 6(1): 100-2.
37. Borsig L, Wong R, Feramisco J et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98(6): 3352-7.
38. van der Pluijm G, Vloedgraven H, Papapoulos S et al. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Invest 1997; 77(6): 665-75.
39. Oleksowicz L, Mrowiec Z, Schwartz E et al. Characterization of tumor-induced platelet aggregation: The role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thromb Res 1995; 79(3): 261-74.
40. Chopra H, Timar J, Rong X et al. Is there a role for the tumor cell integrin alpha IIb beta 3 and cytoskeleton in tumor cell-platelet interaction? Clin Exp Metast 1992; 10(2): 125-37.
41. Pilch J, Habermann R, Felding-Habermann B. Unique ability of integrin alpha(v)beta 3 to support tumor cell arrest under dynamic flow conditions. J Biol Chem 2002; 277(24): 21930-8.
42. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8(11): 1227-34.
43. Andre P, Arbeille B, Drouet V et al. Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig. Arterioscler Thromb Vasc Biol 1996; 16(1): 56-63.
44. Helmke BP, Goldman RD, Davies PF. Rapid displacement of vimentin intermediate filaments in living endothelial cells exposed to flow. Circ Res 2000; 86(7): 745-52.
45. Baumgartner HR, Muggli R, Tschopp TB et al. Platelet adhesion, release and aggregation in flowing blood: Effects of surface properties and platelet function. Thromb Haemost 1976; 35(1): 124-38.
46. Incardona F, Lawler J, Cataldo D et al. Heparin-binding domain, type 1 and type 2 repeats of thrombospondin mediate its interaction with human breast cancer cells. J Cell Biochem 1996; 62(4): 431-42.
47. Loganadane LD, Vassy J, Legrand C et al. Transforming growth factor-beta 1 increases the adhesion of MDA-MB-231 mammary adenocarcinoma cells to the microvascular subendothelium. Cell Adhes Commun 1999; 7(1): 57-71.
48. Haier J, Nasralla MY, Nicolson GL. Beta1-integrin-mediated dynamic adhesion of colon carcinoma cells to extracellular matrix under laminar flow. Clin Exp Metast 1999; 17(5): 377-87
49. Beauvais DM, Rapraeger AC. Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells. Exp Cell Res 2003; 286(2): 219-32.
50. Cohen SA, Trikha M, Mascelli MA. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol Oncol Res 2000; 6(3): 163-74.